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LETTERS
Extended colonic ulcerations in a patient with microscopic
polyangiitis
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M
icroscopic polyangiitis is a necrotising vasculitis
primarily affecting small vessels, with few or no
immune deposits. Patients are characterised by
positive antineutrophil cytoplasmic antibodies (ANCA),
mainly perinuclear pattern. The spectrum of clinical mani-
festations is broad, including the kidney, musculoskeletal
system, lung, gastrointestinal tract, skin, ear, nose, and
throat, and neurological system.1 Although gastrointestinal
disease is noted in half of the patients, the presentation is
usually mild.2 Here, we report a patient with microscopic
polyangiitis with initial presentation of extended colonic
ulcerations and haemorrhage, characterised by a crypt
abscess. To our knowledge, such a finding has not been
reported previously.
CASE REPORT
A 69 year old man was admitted to hospital owing to leg
oedema and body weight loss in the past 3 months. No
systemic disease had previously been noted. He had a poor
appetite and abdominal discomfort, but denied bowel habit
changes, bloody or tarry stool.
On examination, vital signs were stable. Pale conjunctiva,
mild abdominal tenderness, and pitting oedema over the legs
were noted. Laboratory tests showed leucocytes 11.96109/l,
haemoglobin 67 g/l, albumin 225 mmol/l, C reactive protein
1157 mg/l, and erythrocyte sedimentation rate more than
150 mm/1st h. Daily urinary protein loss was 0.7 g. Stool
examination showed positive occult blood. However, the
results of panendoscopy and lower gastrointestinal investiga-
tions were negative.
Intermittent high fever was noted several days after
admission. No infectious focus was identified by repeated
blood and stool cultures. Abdominal computed tomography
disclosed mild inflammation over the mesentery.
Colonoscopy showed markedly swelling mucosa with hae-
morrhage and ulcers from rectum to the cecum (fig 1A). A
pathology examination reported inflammatory infiltrates in
the lamina propria, destruction of the mucosal gland, and a
crypt abscess (fig 1B). Ulcerative colitis was diagnosed,
and mesalazine and prednisolone 30 mg every day were
prescribed.
Sudden onset of haemoptysis occurred 1 week later and
pulmonary haemorrhage was diagnosed. Intravenous
methylprednisolone 20 mg every 8 hours was given, and
the haemoptysis disappeared 1 week later. Repeated urinary
analysis showed a daily protein loss of 4 g. An autoantibody
examination showed negative antinuclear antibodies and
antiglomerular basement membrane antibody. ANCA were
positive (perinuclear pattern, 6320), and further analysis
showed positive antimyeloperoxidase 103 U/ml (normal
range ,20 U/ml). A renal biopsy showed glomerular necro-
sis, cellular crescent, interlobular arteritis, diffuse tubular
atrophy, and few immune deposits. The final diagnosis was
microscopic polyangiitis with a rare presentation of extended
colonic ulcerations. Pulse intravenous cyclophosphamide
700 mg was given and steroid was gradually tapered.
Proteinuria, hypoalbuminaemia, anaemia and inflammatory
measures improved with treatment. He was discharged and
received monthly pulse cyclophosphamide treatment there-
after. Neither abdominal pain nor diarrhoea was noted
during follow up at the outpatient clinic.
Figure 1 (A) The mucosa of the sigmoid colon was hyperaemic,
oedematous, and markedly uneven, with multiple ulcers and
haemorrhage. The ulcers were irregular in shape and varied in size.
Some cotton wool-like vascular pattern (arrow) was also noted in the
surrounding mucosa. (B) Colonic biopsy specimen showing
inflammatory cell infiltrating the lamina propria, destruction of the
mucosal gland, and marked crypt abscess (haematoxylin and eosin,
6200)
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DISCUSSION
In microscopic polyangiitis, necrotising glomerulonephritis is
the most common abnormality and pulmonary capillaritis
often occurs. Perinuclear ANCA are present in more than 60%
of patients, and antimyeloperoxidase antibody is closely
allied.1 Gastrointestinal involvement is usually mild and
there is no report of extended colonic ulcerations and
haemorrhage.2 In addition, colonic biopsy disclosed crypt
abscess, which can be found in ulcerative colitis, infectious
colitis, radiation induced colitis, and graft versus host
disease.3–5 However, such a finding has not been reported
previously in patients with microscopic polyangiitis.
Ulcerative colitis was diagnosed initially according to the
colonoscopic and pathological findings. Pulmonary vasculitis
is very rare in patients with inflammatory bowel diseases.6
Renal disease with necrotising glomerulonephritis is not
commonly seen in patients with ulcerative colitis.7 In
addition, antimyeloperoxidase antibody is usually not
detected in such patients.8 The clinical course of this patient
who had lung and renal manifestations did not favour a
diagnosis of ulcerative colitis. The final diagnosis was
microscopic polyangiitis with gastrointestinal involvement.
Extended colonic ulcerations with haemorrhage have not
been reported previously in patients with microscopic
polyangiitis. Vasculitis should be considered for differential
diagnoses of colonic ulcerations, especially when the pre-
sentation is atypical, to avoid delay of prompt treatment.
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P
ulmonary hypertension is associated with autoimmune
diseases, giving rise to digital ischaemia, including
Raynaud’s phenomenon (RP). As sildenafil, a phospho-
diesterase-5 (PDE-5) inhibitor, relieves the pulmonary
hypertension,1 we suggested that it might also benefit digital
ischaemia and RP symptoms. This report describes the impact
of oral sildenafil (Viagra, donated by Pfizer HK) on three
women with autoimmune disease and progressively severe
digital ischaemia, despite treatment with a variety of drugs,
including intravenous iloprost (fig 1). All patients gave
written informed consent to try this off-label treatment.
CASE REPORTS
A 42 year old woman with dermatomyositis ‘‘sine myositis’’
and thyrotoxicosis (case 1) taking prednisolone, hydroxy-
chloroquine, and carbimazole, experienced regression of
troublesome RP and ischaemic digital ulceration after
receiving diltiazem SR 200 mg/day and thrice monthly
iloprost infusions. Ten months later, antituberculosis chemo-
therapy was started and the steroid dosage reduced, after she
developed a febrile illness with cough, pleuropericardial
effusions, and sputum culture positive for tuberculosis
(TB). Digital gangrene supervened in both hands and both
feet despite daily intravenous iloprost infusions for 2 weeks.
A day after starting sildenafil 50 mg three times a day her
digital circulation and pain improved markedly; facial
flushing was the only adverse reaction. In view of the slightly
deteriorating digital ischaemia and experimental evidence,2 3
we inferred that rifampicin treatment was inducing the
metabolism of sildenafil. Its dosage was therefore doubled.
Symptomatic improvement continued and ischaemic tissues
became demarcated. However, 26 days after starting silde-
nafil she succumbed to uncontrolled pulmonary TB.
A 28 year old woman with scleroderma/lupus (case 2) who
had been receiving diltiazem, domperidone, omeprazole, and
penicillamine for about 4 years presented with progressive
breathlessness. Computed tomography of the thorax sug-
gested fibrosing alveolitis; prednisolone and azathioprine
were started. Thereafter, she incurred occasional chest
infections, other complications, and features of autoimmune
diseases. She then developed persistent high grade fever,
chills, rigors, night sweats, and increasingly severe digital
arthralgia, vasculitis, and ischaemia. A polymerase chain
reaction (PCR) of blood disclosed disseminated TB. Despite
resolution of the sepsis after anti-TB chemotherapy, she
developed progressive ischaemia and impending gangrene of
her fingers, toes, and feet, despite regular infusions of
iloprost for 2 weeks. One day after starting sildenafil 50 mg
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three times a day, all four extremities showed marked
symptomatic improvement, becoming warm, less painful,
and less discoloured. Her digital vasculitis resolved; weeks
later necrotic zones became demarcated and autoamputated.
Owing to resurgence of active lupus, her prednisolone dosage
was increased; her haematological/serological abnormalities
regressed. After 48 days of sildenafil treatment, tadalafil
(Cialis) 10 mg once daily was substituted for 78 more days,
without any adverse reaction. Currently, the patient remains
well and can stand.
A 76 year old woman with prior hypertension and
ischaemic heart disease (case 3) presented with erythema-
tous facial and finger rashes, myalgia, finger and toe
ischaemic lesions, and proximal muscle weakness. Dermato-
myositis and a disseminated malignancy were diagnosed.
After mutually agreeing to stop further investigation,
prednisolone treatment was started. Her digital ischaemia
responded poorly to diltiazem SR and any improvement
during iloprost infusions disappeared when they stopped.
After 12 days and despite her past medical history, sildenafil
treatment was cautiously started, with immediate reduction
in peripheral pain and ischaemia and healing of toe ulcers.
Although well tolerated, sildenafil was discontinued after
3 weeks, as the patient required treatment with nitrates.
DISCUSSION
All three patients had immediate, subjective and objective
improvements after initiating sildenafil, which was entirely
consistent with Lichtenstein’s observations, except that our
patients were very severely afflicted.4 In two patients,
worsening RP and digital ischaemia appeared during active
TB, consistent with the effects of sepsis.5 Rifampicin, a power-
ful inducer of relevant P450 enzymes (apt to enhance sildenafil
elimination2 3), appeared to affect their management. These
Figure 1 (A), (B), and (C) refer to
cases 1, 2, and 3, respectively. In all
three cases, ischaemia of viable tissues
resolved after treatment with sildenafil
(and tadalafil in case 2). (B) shows that
increased finger extension became
possible after treatment.
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observations merit a randomised controlled trial to investi-
gate the treatment of disabling RP with oral PDE-5 inhibitors.
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Hereditary C1q deficiency and secondary Sjo¨gren’s
syndrome
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A
13 year old Turkish boy with a known C1q deficiency
and SLE-like disease developed recurrent parotitis.
Investigations confirmed a secondary Sjo¨gren’s syn-
drome (SS). As far as we know, the association between C1q
deficiency and SS has not been described before. The
potential role of C1q in the pathogenesis of SS and systemic
lupus erythematosus (SLE) might stimulate further research
in understanding the pathogenesis of these and other
autoimmune diseases. Screening patients with SS for
complement deficiencies, including C1q deficiency, seems
indicated.
Deficiency of the complement component C1q is a rare
genetic disorder with susceptibility to recurrent infections
with polysaccharide encapsulated micro-organisms and a
high prevalence of autoimmune phenomena, most often SLE.
CASE REPORT
At the age of 4 years a boy of consanguineous Turkish
descent had meningitis of unknown origin. At the age of
8 years he presented with meningococcal sepsis and menin-
gitis. In the late convalescent phase of this infection he
developed arthritis of his right elbow and pericarditis. At the
age of 10 years he was admitted owing to lobular pneumonia.
Immunological studies at that time demonstrated no func-
tional or antigenic activity of C1q based on a homozygous
Glu-86 stop mutation in the C1qA gene exon 2. Both parents
and a sibling sister were found to be asymptomatic
heterozygous carriers. His sibling brother, who also developed
SLE-like symptoms, was homozygous for this mutation.
At the age of 13 years the patient developed recurrent
arthritis of the ankle and elbow. Two years later he presented
with six episodes of alternate right and left parotitis.
There were no complaints of dry mouth or dry eyes.
Ultrasonography of the parotid gland during an episode of
parotitis disclosed diffuse swelling. Salivary scintigraphy
showed delayed tracer uptake. Ocular examination showed
some corneal erosion, a normal Schirmer test, and a tear
break up time of 10 seconds. A salivary gland biopsy showed
lymphocytic sialoadenitis with a focus score of 4 and a
percentage of plasma cells containing IgA of 9%, consistent
with SS. Microscopic haematuria and proteinuria were not
present. Immunological studies showed positive antinuclear
antibodies (ANA), RNP antibodies, anti-Sm antibodies, anti-
SSA antibodies, and a positive rheumatoid factor (RF). Anti-
SSB antibodies and anti-dsDNA antibodies were not
detected. A direct Coombs test and a serological test for
syphilis were negative. Serum immunoglobulins were slightly
raised. C3 and C4 were normal.
DISCUSSION
In our patient a homozygous point mutation in the C1qA
gene was demonstrated that has earlier been described in five
families from the Slovak republic and Turkey.1 With arthritis,
a positive ANA test, and anti-Sm antibodies our patient has
an SLE-like disease.2 Patients with SLE commonly have sicca
symptoms, which may be related to the concomitant
occurrence of SS.3 Secondary SS, in which the disease
coexists with an autoimmune disease, is defined by the
presence of either ocular or oral symptoms and two of four
objective classification criteria.4 Our patient with recurrent
swollen salivary glands, autoantibodies to ANA, RF, and SSA,
a salivary scintigraphy showing delayed uptake, and biopsy
findings consistent with SS, meets the full criteria for
secondary SS.
These observations suggest that absence or abnormal
function of C1q leads to susceptibility for SLE and SS. This
may be due to ineffective immune complex clearance that
causes tissue injury, exposes autoantigens, and stimulates an
autoantibody response.5 In this respect it is significant that
our patient had late onset reactive arthritis and pericarditis
related to his meningococcal disease, which is also mediated
by immune complexes.6 Other data suggest a defective
clearance of apoptotic cells, which promotes accumulation
of nucleosomes (suggested antigens in SLE), which in turn
drives an autoimmune response.7
In conclusion we report a patient with C1q deficiency, SLE-
like disease, and secondary SS. This is the first time that an
association between C1q deficiency and SS has been reported.
It suggests a role for C1q in the pathogenesis of autoimmune
diseases, possibly due to ineffective immune complex
clearing or defective apoptosis, and warrants further
research.
Screening of patients with C1q deficiency for SS, but
especially screening of patients with SS for complement
deficiencies, including C1q deficiency, seems indicated.
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Acute pneumonitis starting 2 hours after intramuscular gold
administration in a patient with rheumatoid arthritis
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G
old salts have been used for the treatment of
rheumatoid arthritis (RA) for over 50 years.1 Their
use is limited by the incidence of adverse reactions,
including pneumonitis. Most case reports describe pneumo-
nitis developing after a cumulative dose of several hundred
milligrams.2 Only four cases of lung disease have been
reported with a cumulative dose of ,100 mg.3
Here we report a case of gold pneumonitis, starting only
2 hours after the first maintenance dose of 20 mg was
administered.
CASE REPORT
A 54 year old woman with RA had been followed up since
1984, her arthritis being well controlled with chloroquine. In
1997 her disease had flared up, and alternative disease
modifying drugs were introduced—sulfasalazine, then metho-
trexate (both of were stopped because of adverse side effects),
and finally, leflunomide. The last of these caused leucopenia
and hypertension (controlled with bendrofluazide and
ramipril) and hence was discontinued. Subsequently, her
disease became more active again with prolonged joint
stiffness, hand synovitis, and erythrocyte sedimentation rate
(ESR) 102 mm/1st h.
Treatment was started with gold injections, with a test
dose of 10 mg (no adverse effects noted), followed a week
later by a dose of 20 mg. About 2 hours afterwards she
complained of dizziness, nausea, then she developed a cough
and breathlessness. She was admitted to hospital later that
day. On examination she was apyrexial, tachypnoeic,
cyanosed (oxygen saturation 79% on air), pulse 110/minute,
blood pressure 80/46, heart sounds normal, and had no signs
of heart failure.
Investigations showed haemoglobin of 103 g/l with normal
white cell and platelet counts. C reactive protein was 115 mg/l
and troponin-I (a marker for myocardial infarction) was
normal at 0.1 mg/l. Arterial blood gases on air showed a
type 1 respiratory failure pattern. A chest x ray examination
showed bilateral lower zone alveolar shadowing. An
echocardiogram showed a normal ejection fraction.
After high dose oxygen treatment, intravenous hydrocorti-
sone 100 mg, and intramuscular adrenaline 0.5 mg 1:1000,
some improvement was seen clinically, oxygen saturation
rising to 90% and blood pressure to 116/69. She was admitted
to the high dependency unit and treatment started with pulse
methylprednisolone 1 g daily, nasal continuous positive
airway pressure ventilation, and required parenteral nutri-
tion. On the day after her admission, she developed a
generalised macular rash. Over the next 7 days her clinical
condition improved (serial chest x ray examinations over this
period showed clearing of the previous alveolar shadowing),
and her treatment was changed to a reducing regimen of oral
steroids. She was discharged, continuing frumil once daily
and prednisolone 5 mg daily. Her arthritis was inactive and
blood pressure 110/70. The ESR was 22 mm/1st h.
During her admission, it was considered that owing to the
severity of her illness she was not fit enough to have other
investigations—for example, computed tomography chest
scan, bronchoalveolar lavage, and pulmonary function tests.
The gold was discontinued and her arthritis remains in
remission.
DISCUSSION
Gold pneumonitis is a potentially fatal complication of gold
salt treatment. This case illustrates two important points in
management:
N Some of the early symptoms could have been confused
with a nitritoid reaction. Indeed, hypertensive patients
with RA who are taking angiotensin converting enzyme
inhibitors (in this case ramipril) show a higher frequency
of such reactions4 even if long term gold treatment is
established. This combination should be avoided where
possible.
N The clinical picture started to develop after only 2 hours of
gold administration with just a 30 mg cumulative gold
dose. Most case reports have suggested higher cumulative
dose exposure2 5 6 and longer duration of treatment. To our
knowledge such a florid onset has not been previously
reported.
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An unusual complication of appendicitis
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A
32 year old man presented with a 3 day history of fever,
central abdominal pain, and frequent loose bowel
motions without blood or mucus. The pain had
recently shifted to his right iliac fossa. He had previously
been well and he was receiving no regular drugs. On
examination he was systemically well, but rebound tender-
ness was noted in the right iliac fossa, and C reactive protein
(CRP) was raised (78 mg/l, reference range,10). A diagnosis
of acute appendicitis was made and he underwent appendi-
cectomy. Histology disclosed serosal congestion with a
predominantly eosinophilic infiltrate in the mucosa and
deeper layers.
Postoperatively the fever resolved, but the diarrhoea
continued for several weeks. Two weeks later he developed
a right knee effusion associated with raised inflammatory
markers (CRP 37 mg/l). Subsequently, the left knee and right
elbow also swelled, with 1 hour of morning stiffness.
Synovial fluid from the knee and blood cultures was sterile;
the diarrhoea was mild and stool cultures were not
performed. Treatment with non-steroidal anti-inflammatory
drugs and sulfasalazine was started. The arthritis resolved
over the next 3 months, with normalisation of inflammatory
markers; at the last review the patient had stopped all
treatment and was well.
Serological testing showed raised titres (1/1280) of anti-
bodies to Yersinia enterocolitica O:3 (>1/160 being considered
significant), which remained at 1/640 3 months later.
On the basis of the clinical picture and serology a diagnosis
of yersiniosis was made.
DISCUSSION
Reactive arthritis following enteric Y enterocolitica infection is
well described.1 Y enterocolitica and Y pseudotuberculosis are also
well known causes of mesenteric adenitis, ileocolitis, and
appendicitis,2 but reports of reactive arthritis following Y
enterocolitica appendicitis are surprisingly rare.3 4
Pure cultures of Y enterocolitica have occasionally been
isolated from acutely inflamed appendices, suggesting a
primary pathogenic role for this species.5 Serological evidence
of acute infection by Y enterocolitica was also reported in three
of 90 patients with acute appendicitis;6 of these, two had
postoperative diarrhoea. In another series7 evidence of Y
enterocolitica or Y pseudotuberculosis was found by a polymerase
chain reaction technique in 10 of 40 cases of granulomatous
appendicitis but in none of 30 cases of non-granulomatous
appendicitis.
An unexpected feature of this case was that granulomas
were not seen on histology. The significance of the
eosinophilia is uncertain, but in other respects the histology
was typical of acute appendicitis. The association of
appendicitis and yersinia induced reactive arthritis appears
to be surprisingly unusual, despite the common occurrence of
each condition individually. Nevertheless, it is clearly
important for physicians to be aware that abdominal pain
in patients with reactive arthritis may signify the potentially
lethal complication of appendicitis, and for surgeons to be
aware that appendicitis may be complicated by reactive
arthritis.
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Interferon alfa in protracted arthritis of familial
Mediterranean fever: a robust alternative for synovectomy
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A
17 year old girl was admitted to our rheumatology
clinic with right knee pain and swelling for the past
3 months. A diagnosis of familial Mediterranean fever
(FMF) had been made 8 years previously; she had recurrent
attacks of fever, abdominal pain, and knee arthritis. She had
been using colchicine 1.5 mg/day regularly since then.
Although her abdominal attacks and fever had subsided
with colchicine treatment, recurrent mild knee attacks
occurred almost every month. Two years ago she was found
to have the homozygous M694V gene mutation for FMF.
Three months ago, she was admitted to hospital owing to
monarthritis in her right knee—but this time with a
prolonged and severe episode. She was given antibiotics,
and a suspected diagnosis of septic arthritis was made. As the
cultures did not yield any bacterial growth and her symptoms
persisted, she applied to our department.
A physical examination disclosed painful and limited
movement, swelling and warmth in the right knee joint.
Laboratory findings were as follows: erythrocyte sedimenta-
tion rate: 96 mm/1st h, C reactive protein: 165 mg/l (0–8),
fibrinogen: 8.5 g/l (1.4–4.3). Protracted arthritis of FMF was
diagnosed and the dose of colchicine was increased to 2 mg/
day. Ten days later, she was seen on a control visit with
complaints of abdominal pain, diarrhoea, skin rash—prob-
ably due to colchicine—and persistent knee arthritis, which
did not respond to colchicine treatment. Accordingly,
interferon alfa 4.5 million IU (twice a week) was started
and the colchicine dose was decreased to 1.5 mg/day.
Thereafter, she has been followed up every 10 days for
3 months and her knee arthritis has disappeared and the
laboratory measures have improved (table 1). She is still
being routinely followed up and is completely normal with
the above mentioned regimen of interferon alfa and
colchicine together with a protocol of isometric quadriceps
strengthening exercises.
DISCUSSION
Arthritis in FMF usually comprises acute attacks, with
complete resolution within a few days or 2 weeks. It is more
common in patients with the homozygous M694V gene
mutation. Occasionally, the attacks are protracted, lasting for
several months, and chronic joint disease has been estimated
to contribute about 5–10% to the joint manifestations in
FMF.1 2 However, once degenerative or necrotic changes
ensue, the recurrent attacks of arthritis are no longer
punctuated by symptom-free intervals. Additionally, the
irreversible morphological changes in the joints become
non-responsive to colchicine, corticosteroids, or non-steroidal
anti-inflammatory drug treatment. Although ruling out a
coexisting chronic inflammatory arthritis should remain a
prerequisite,3 surgery is usually warranted in such cases.1 4 5
To the best of our knowledge, a medical treatment alternative
for these patients that would make synovectomy unnecessary
has not been reported. Only one report, by Tunca et al, has
described favourable effects of interferon alfa on the
abdominal attacks of seven patients with FMF.6 As recent
studies have disclosed up regulation of the MEFV gene by
interferon,7 the mechanism—which could not have been
substantiated previously—has become evident. Thus, overall,
we advocate the use of inteferon alfa as an adjunct for the
treatment of colchicine resistant arthritis attacks in FMF.
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Table 1 The changes in the laboratory variables of the
patient with interferon alfa treatment
Interferon treatment
ESR CRP Fibrinogen
(mm/1st h) (mg/l) (g/l)
Immediately before 61 106 8.8
Two weeks after 35 11 4.9
Six weeks after 30 4 4.8
Twelve weeks after 25 4 4.5
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Transient bone marrow oedema in a child
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T
ransient bone marrow oedema (TBMO) is an uncommon
condition associated with joint and bone pain on activity.
The most common localisation is the proximal femur,
and it mainly affects only one bone.1 Reports of bone marrow
oedema in children are scarce.2–4
CASE REPORT
An 8 year old boy was referred to hospital owing to difficulty
in walking. He had started ski jumping 2 weeks earlier, but
his history showed no injuries in the extremities. He
complained of pain in the knees, ankles, and wrists. Mild
fever and signs of upper respiratory tract infection were
detected and reactive arthritis was suspected. Treatment with
naproxen was started and he was discharged. Ultrasound
investigation showed only slight symmetrical oedema in the
ankle joints. Haemoglobin, white blood cell count, and
thrombocytes were all within normal limits.
During the next 2 weeks, the pain was localised in both
feet and the patient was hardly able to walk. Palpation and
compression of both feet was very painful. An x ray
examination which was carried out 2 weeks after the first
visit showed marked osteopenia in the tarsal area and in
distal parts of the tibia and fibula (fig 1). A magnetic
resonance imaging (MRI) scan was performed 4 weeks after
the beginning of the symptoms showed marked bone marrow
oedema (fig 1). Transient osteoporosis was suspected. Bone
scintigraphy showed areas of hyperperfusion both in the feet
and the hands. An MRI scan was subsequently obtained of
the hands also, which also showed bone marrow oedema.
Axial bone mineral density was measured by dual x ray
absorptiometry and was normal. Serum calcium, phosphate,
parathyroid hormone, alkaline phosphatase (AP), and
vitamin D metabolites were normal. However, bone markers
were raised (table 1).
During follow up the pain became less intensive and after
3 months, the condition had resolved clinically, although an
MRI scan was still abnormal. MRI normalised in 8 months.
However, serum osteocalcin values remained raised, suggest-
ing increased bone remodelling (table 1).
DISCUSSION
There are no data on the incidence of TBMO in children.
However, it seems to be a relatively rare cause of foot and
ankle pain also in adults.5 In another study of 1123 patients
referred for MRI imaging of the foot, 72 patients with
oedema-like bone marrow abnormalities were registered.6
The aetiology of TBMO is unknown but it may be
associated with local vascular disturbances, microtrauma,
bone contusion, or altered biomechanics.6 7 The x ray
examination is usually either normal or shows localised
osteoporosis, as in our case. However, osteoporosis is a rare
finding in bone biopsies.8 Histological studies have suggested
ischaemic origin.9
The definitive diagnosis of TBMO is made by MRI. Bone
contusion and bone bruises normally manifest as focal areas
of low signal intensity in T1 weighted images and increased
signal intensity in T2 weighted images, whereas bone oedema
shows diffuse changes of intensity.1 In our patient marked
bone marrow oedema was seen in both feet and hands.
Because of the unknown aetiology of bone changes we
measured biochemical markers of bone metabolism. Serum
AP values were within the normal range but both osteocalcin
and procollagen type I C-peptide were high and remained
high, although the clinical condition was relieved. However,
except for AP, interpretation of these results is difficult
because there are no established normative data for bone
markers in children.10
The treatment of TBMO is not well established. Core
decompression and vasodilatator treatment with iloprost
have been suggested.4 7 Conservative treatment aims at
protecting bone from weight bearing, both to prevent collapse
of the articular surface and provide relief from pain. In this
Figure 1 A radiograph showing marked osteoporosis in the tarsal and metatarsal bones. In the MRI scan, hyperintesity in the tarsal bones can be seen
as a sign of oedema in T2 weighted images.
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patient the use of anti-inflammatory drugs and rest relatively
rapidly relieved pain, although changes in the MRI scan were
seen for several months.
The aetiology of TBMO in our patient remains unknown:
his history disclosed no trauma, but it is possible that ski
jumping and hence either bone contusion or abnormal stress
might have been the predisposing factors.
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Table 1 Laboratory data at baseline and during follow up
AP (U/l) PICP (mg/l) ICTP (mg/l) OC (mg/l) Ca (mmol/l) Pi (mmol/l)
(250–850)* (38–202)* (1.6–4.6)* (1–11)* (2.2–2.65)* (1.2–1.8)*
Baseline 556 2.42 1.46
1 Month 629 840 13 81.5
8 Months 649 15.6 136.6
12 Months 640 726 13.8 112.7
*Normal range.
AP, alkaline phosphatase; PICP, procollagen type I C-peptide; ICTP, type I collagen carboxy terminal telopeptide;
OC, osteocalcin; Pi, phosphate.
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J
oint lavage, although its efficacy is still under debate,1–6
seems to be effective, mostly, in the treatment of
gonarthritis associated or not with chondrocalcinosis
(CC).2 3 7 Paradoxically, acute pseudogout is a complication
of this technique.8 Our study aimed at evaluating the incidence
of pseudogout in 73 patients with gonarthritis, associated or
not with CC, who underwent arthroscopic lavage (AL).
METHODS AND RESULTS
In this retrospective study we assessed the incidence of
pseudogout attacks that occurred 24 hours after surgery in 73
consecutive patients with gonarthritis (52 women (71%), 21
men (29%)), who underwent AL of the knee at our hospital.
All the patients had medium-severe symptomatic osteo-
arthritis, according to Kellgren and Lawrence’s classification
(II-III-IV degrees),9 and were unresponsive to drugs (that is
non-steroidal anti-inflammatory drugs, analgesics, disease
modifying osteoarthritis drugs) and rehabilitative treatment.
AL was carried out with an arthroscopic sheath 5.5 mm in
diameter and 12 cm long, preceded by intra-articular
carbocaine 2%. Twenty three patients had radiological or
laboratory signs of CC, including x ray evidence of meniscal
and cartilaginous opacities and/or birefringent positive
intra- and extracellular calcium pyrophosphate crystals
(CPPD) in the synovial fluid (group A). The remaining 50
patients had gonarthritis with no evidence of CC (group B)
(table 1). They were followed up clinically 1 and 10 days after
the AL.
The relative risk of the incidence of pseudogout in group A
compared with group B patients was estimated from the
analysis of contingency tables, by odds ratios (ORs); the 95%
confidence interval (95% CI) was also calculated. The
differences between the two groups were studied by the x2
and Fisher tests applied to a 262 contingency table. The
association of age, sex, and radiographic osteoarthritis grade
with pseudogout incidence after lavage was evaluated,
respectively, by unpaired t test, Fisher test, and x2 test
carried out on contingency tables. A value of p,0.05 was
considered significant.
Of the 73 patients treated (mean (SD) age 59.4 (6.7)), nine
(12%) had an arthritic episode within 24 hours after surgery.
In each of these cases, wet sinovianalysis confirmed the
inflammatory nature of the phenomenon (leucocyte counts
between 56109 and 306109/l); polarising microscopy demon-
strated the presence of CPPD. In all nine cases, culture and
bacterioscopic examination of the synovial fluids were
negative. The joint was injected with steroids, and the
phenomenon resolved completely within 24 hours.
Six of the nine patients with pseudogout attack (26%)
belonged to group A, while three (6%) belonged to group B.
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The OR of group A compared with group B was estimated to
be 5.5 (95% CI 1.24 to 24.60; p,0.05) (table 1).
DISCUSSION
The results of this study underline the significant incidence
(26%) of pseudogout as a possible complication of AL in
patients with CC (table I).
Among the pathogenic hypotheses, mechanical-traumatic
is the most likely; in fact, the lavage fluid could promote
‘‘crystal shedding’’, due to the release of CPPD embedded in
the joint tissues.8
Furthermore, it should be noted that this complication was
also documented in three patients with gonarthritis without
radiological or laboratory evidence of CC. This might be due
to the fact that in a variable percentage of cases, microscopy
for crystals in synovial fluid may yield false negative
results.3 10 According to our data the age, sex, and radio-
graphic grade of the patients had no significant association
with the incidence of pseudogout after lavage.
In conclusion, pseudogout should be considered as a
possible complication of AL, mainly in patients with CC,
with about a fivefold risk compared with patients with
osteoarthritis.
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Table 1 Demographic data of the patients and incidence
of pseudogout in groups A and B
Group A Group B Total
Patients treated, No (%) 23 (32) 50 (68) 73
Age, mean (SD) 60.4 (4.2) 58.2 (6.8) 59.4 (6.7)
Sex (F/M) 15/8 37/13 52/21
Pseudogout attacks, No (%) 6 (26)* 3 (6) 9 (12)
*p,0.05.
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